Rapport Therapeutics (RAPP) Other Accumulated Expenses (2023 - 2026)

Rapport Therapeutics (RAPP) has reported Other Accumulated Expenses for 4 consecutive years, with $144000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 55.56% year-over-year to $144000.0; the TTM figure through Mar 2026 stood at $144000.0 (down 55.56% YoY), while the FY2025 annual figure was $6000.0, down 98.72% from the prior year.
• Other Accumulated Expenses grew to $144000.0 in Q1 2026 per RAPP's latest filing, from $6000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $469000.0 in Q4 2024 and bottomed at $6000.0 in Q4 2025.
• Historically, Other Accumulated Expenses has averaged $208666.7 across 4 years, with a median of $144000.0 in 2026.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses surged 311.4% — and 2025, when it slumped 98.72%.
• Rapport Therapeutics' Other Accumulated Expenses stood at $114000.0 in 2023, then surged by 311.4% to $469000.0 in 2024, then plunged by 98.72% to $6000.0 in 2025, then soared by 2300.0% to $144000.0 in 2026.
• Business Quant data shows RAPP's Other Accumulated Expenses at $144000.0 in Q1 2026, $6000.0 in Q4 2025, and $104000.0 in Q3 2025.